No Data
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Nurix Therapeutics Receives PRIME Designation From the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Express News | Nurix Therapeutics Receives Prime Designation From the European Medicines Agency for Nx-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
Express News | Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024
Nurix Therapeutics Down Over 10%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk